Cyclodextrin-based carriers for Topical delivery of Anti-Inflammatory Agents

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2011, Pages 230-239

  Oliveira, Rita ^a   Coelho, Pedro ^a  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Anti inflammatory; Complexation; Cyclodextrins; Delivery systems; Liposomes; Microemulsions; Solid lipid nanoparticles; Topical delivery; Transdermal delivery

Indexed keywords

ANTIINFLAMMATORY AGENT; BETAMETHASONE; BUPRENORPHINE; CELECOXIB; CORTICOSTERONE; CYCLODEXTRIN; DEXAMETHASONE; DICLOFENAC; DRUG VEHICLE; FLURBIPROFEN; HYDROCORTISONE; INDOMETACIN; KETOPROFEN; KETOROLAC; LIPOSOME; MELOXICAM; MORPHINE; NALTREXONE; NANOPARTICLE; NAPROXEN; PENETRATION ENHANCING AGENT; PIROXICAM; ROFECOXIB; SOLID LIPID NANOPARTICLE; TENOXICAM; WATER;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; FIRST PASS EFFECT; MICROEMULSION; SKIN PERMEABILITY; STRATUM CORNEUM; THERMODYNAMICS;

EID: 79960577009     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011109030230     Document Type: Article

References (102)

1. Schäfer-Korting, M.; Mehnert, W.; Korting, H.-C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59(6), 427-443.
2. Hsieh, D., Ed. Drug Permeation Enhancement: theory and applications; Marcel Dekker: New York, 1994.
3. Mosher, G.; Thompson, D.O. Complexation and cyclodextrins, In: Encyclopedia of Pharmaceutical Technology; Swarbrick, J. C., Ed.; Marcel Dekker: New York, 2002, pp. 531-558.
4. Loftsson, T.; Brewster M.E. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J. Pharm. Sci., 1996, 85(10), 1017-1025.
5. Loftsson, T.; Masson, M. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm., 2001, 225(1-2), 15-30.
6. Stella, V.J.; Rao, V.M.; Zannou, E.A.; Zia, V.V. Mechanisms of drug release from cyclodextrin complexes. Adv. Drug Deliv. Rev., 1999, 36(1), 3-16.
7. Loftsson, T. Cyclodextrins and the Biopharmaceutics classification system of drugs. J. Inclusion Phenom. Macrocyclic Chem., 2002, 44(1-4), 63-67.
8. Uekama, K.; Hirayama, F.; Irie, T. Cyclodextrin drug carrier systems. Chem. Rev., 1998, 98(5), 2045-2076.
9. Dias, M.M.; Raghavan, S.L.; Pellett, M.A.; Hadgraft, J. The effect of beta-cyclodextrins on the permeation of diclofenac from supersaturated solutions. Int. J. Pharm., 2003, 263(1-2), 173-81.
10. Walters, K.A. Dermatological and transdermal formulations.; New York: Marcel Dekker, 2002.
11. Benson, H.A. Transdermal drug delivery: penetration enhancement techniques. Curr. Drug Deliv., 2005, 2(1), 23-33.
12. Lieb, L.M.; Liimatta, A.P.; Bryan, R.N.; Brown, B.D.; Krueger, G.G. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. J. Pharm. Sci., 1997, 86(9), 1022-9.
13. Mura, S.; Pirot, F.; Manconi, M.; Falson, F.; Fadda, A.M. Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J. Drug Targeting, 2007, 15(2), 101-108.
14. Suhonen, T.M.; Bouwstra, J.A.; Urtti, A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural. J. Control. Release, 1999, 59, 149-161.
15. Boddé, H.E.; Kruithof, M.A.M.; Brussee, J.; Koerten, H.K. Visualization of normal and enhanced HgCl2 transport through human skin in vitro. Int. J. Pharm., 1989, 53, 13-24.
16. Fang, J.Y.; Leu, Y.L. Prodrug strategy for enhancing drug delivery via skin. Curr. Drug Discov. Technol., 2006, 3(3), 211-24.
17. Bonina, F.P.; Puglia, C.; Barbuzzi, T.; de Caprariis, P.; Palagiano, F.; Rimoli, M.G.; Saija, A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. European J. Pharm. Sci., 2001, 14(2), 123-134.
18. Rautio, J.; Nevalainen, T.; Taipale, H.; Vepsäläinen, J.; Gynther, J.; Laine, K.; Järvinen, T. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci., 2000, 11(2), 157-163.
19. Qandil, A.; Al-Nabulsi, S.; Al-Taani, B.; Tashtoush, B. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery. Drug Dev. Ind. Pharm., 2008, 34(10), 1054-63.
20. Stinchcomb A.L.; Swaan, P.W.; Ekabo, O.; Harris, K.K.; Browe, J.; Hammell, D.C.; Cooperman, T.A.; Pearsall, M. Straight-chain naltrexone ester prodrugs: Diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci., 2002, 91(12), 2571-2578.
21. Vaddi, H.K.; Banks, S.L.; Chen, J.; Hammell, D.C.; Crooks, P.A.; Stinchcomb, A.L. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J. Pharm. Sci., 2009, 98(8), 2611-25.
22. Wang, J.J.; Sung, K.C., Hu, O.Y.P.; Yeh, C.H.; Fang, J.Y. Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study. J. Pharm. Pharmacol., 2007, 59(7), 917-25.
23. Pellet, M.; Raghavan, S.L.; Hadgraft, J.; Davis, A.F. The Application of Supersaturated Systems to Percutaneous Drug Delivery, In Transdermal Drug Delivery, Guy, R.; Hadgraft, J., Ed.; Marcel Dekker: New York, 2003; Vol. 123, pp. 305-326.
24. Moser, K.; Kriwet, K.; Froehlich, C.; Kalia, Y.N.; Guy, R.H. Supersaturation: Enhancement of skin penetration and permeation of a lipophilic drug. Pharm. Res., 2001, 18(7), 1006-1011.
25. Moser, K.; Kriwet, K.; Kalia, Y.N.; Guy, R.H. Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J. Control. Release, 2001, 73(2-3), 245-253.
26. Jones, S.A.; Reid, M.L.; Brown, M.B. Determining degree of saturation after application of transiently supersaturated metered dose aerosols for topical delivery of corticosteroids. J. Pharm. Sci., 2009, 98(2), 543-54.
27. Leichtnam, M.-L.; Rolland, H.; Wüthrich, P.; Guy, R. H. Enhancement of transdermal testosterone delivery by supersaturation. J. Pharm. Sci., 2006, 95(11), 2373-9.
28. Loftsson, T. Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers. Pharmazie, 1998, 53(11), 733-40.
29. Yong, C.S.; Jung, S.H.; Rhee, J.D.; Choi, H.G.; Lee, B.J.; Kim, D.C.; Choi, Y.W.; Kim, C.K. Improved solubility and in vitro dissolution of ibuprofen from poloxamer gel using eutectic mixture with menthol. Drug Deliv., 2003, 10(3), 179-183.
30. Stott, P.W.; Williams, A.C.; Barry, B.W. Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: a melting point depression effect. Int. J. Pharm., 2001, 219(1-2), 161-176.
31. Fiala, S.; Jones, S.A.; Brown, M.B. A fundamental investigation into the effects of eutectic formation on transmembrane transport. Int. J. Pharm., 2010, 393(1-2), 68-73.
32. Elsayed, M.M.; Abdallah, O.Y.; Naggar, V.F.; Khalafallah, N.M. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int. J. Pharm., 2007, 332(1-2), 1-16.
33. Jain, S.K.; Gupta, Y.; Jain, A.; Rai, K. Enhanced transdermal delivery of acyclovir sodium via elastic liposomes. Drug Deliv., 2008, 15(3), 141-147.
34. Mishra, D.; Garg, M.; Dubey, V.; Jain, S.; Jain, N.K. Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: Propranolol hydrochloride. J. Pharm. Sci., 2007, 96(1), 145-155.
35. Maestrelli, F.; González-Rodríguez, M.L.; Rabasco, A.M.; Mura, P. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int. J. Pharm., 2006, 312(1-2), 53-60.
36. Dubey, V.; Mishra, D.; Nahar, M.; Jain, N.K. Vesicles as tools for the modulation of skin permeability. Expert Opin. Drug Deliv., 2007, 4(6), 579-593.
37. Schafer-Korting, M.; Mehnert, W.G.; Korting, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59(6), 427-443.
38. Wissing, S.A.; Muller, R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity--in vivo study. Eur. J. Pharm. Biopharm., 2003, 56(1), 67-72.
39. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev., 2004, 56(5), 603-18.
40. Hadgraft, J. Skin deep. Eur. J. Pharm. Biopharm., 2004, 58(2), 291-299.
41. Barry, B.W. Lipid-Protein-Partitioning Theory of Skin Penetration Enhancement. J. Control. Release, 1991, 15(3) 237-248.
42. Finnin, B.C.; Morgan, T.M. Transdermal penetration enhancers: Applications, limitations, and potential. J. Pharm. Sci., 1999, 88(10), 955-958.
43. Vollmer, U.; Müller, B.; Peeters, J.; Mesens, J.; Wilffert, B.; Peters, T. A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats. J. Pharm. Pharmacol., 1994, 46(1), 19-22.
44. Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci., 1996, 85(10), 1017-25.
45. Shaker, D.S.; Ghanem, A.H.; Li, S.K.; Warner, K.S.; Hashem, F.M.; Higuchi, W.I. Mechanistic studies of the effect of hydroxypropyl-beta-cyclodextrin on in vitro transdermal permeation of corticosterone through hairless mouse skin. Int. J. Pharm., 2003, 253(1-2), 1-11.
46. Loftsson, T.; Vogensen, S.B.; Brewster, M.E.; Konrádsdóttir, F. Effects of cyclodextrins on Drug Deliv. through biological membranes. J. Pharm. Sci., 2007, 96(10), 2532-2546.
47. Kear, C.L.; Yang, J.; Godwin, D.A.; Felton, L.A. Investigation into the mechanism by which cyclodextrins influence transdermal Drug Deliv. Drug Dev. Ind. Pharm., 2008, 34(7), 692-7.
48. Matsuda, H.; Arima, H. Cyclodextrins in transdermal and rectal delivery. Adv. Drug Deliv. Rev., 1999, 36(1) 81-99.
49. Lopez, R.F.V.; Collett, J.H.; Bentley, M.V.L.B. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone. Int. J. Pharm., 2000, 200(1), 127-132.
50. Doliwa, A.; Santoyo, S.; Ygartua, P. Influence of piroxicam: hydroxypropyl-beta-cyclodextuin complexation on the in vitro permeation and skin retention of piroxicam. Skin Pharm. Appl. Skin Physiol., 2001. 14(2), 97-107.
51. Challa, R.; Ahuja, A.; Ali, J.; Khar, R.K. Cyclodextrins in Drug Deliv.: An updated review. Aaps Pharmscitech, 2005, 6(2), E329-57.
52. Preiss, A.; Mehnert, W.; Fromming, K.H. Penetration of hydrocortisone into excised human skin under the influence of cyclodextrins. Pharmazie, 1995, 50(2), 121-6.
53. Larrucea, E.; Arellano, A.; Santoyo, S.; Ygartua, P. Interaction of tenoxicam with cyclodextrins and its influence on the in vitro percutaneous penetration of the drug. Drug Dev. Ind. Pharm., 2001, 27(3), 251-60.
54. Loftsson, T. Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers. Pharmazie, 1998, 53(11), 733-740.
55. Zi, P.; Yang, X.; Kuang, H.; Yang, Y.; Yu, L. Effect of HPbetaCD on solubility and transdermal delivery of capsaicin through rat skin. Int. J. Pharm., 2008, 358(1-2), 151-8.
56. Ohtani, Y.; Irie, T.; Uekama, K.; Fukunaga, K.; Pitha, J. Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur. J. Biochem., 1989, 186(1-2), 17-22.
57. Ventura, C.A.; Fresta, M.; Paolino, D.; Pedotti, S.; Corsaro, A.; Puglisi, G. Biomembrane model interaction and percutaneous absorption of papaverine through rat skin: effects of cyclodextrins as penetration enhancers. J. Drug Targeting, 2001, 9(5), 379-93.
58. Legendre, J.Y.; Rault, I.; Petit, A.; Luijten, W.; Demuynck, I.; Horvath, S.; Ginot, Y.M.; Cuine A. Effects of beta-cyclodextrins on skin: Implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur. J. Pharm. Sci., 1995, 3(6), 311-322.
59. Williams, A.C.; Shatri, S.R.; Barry, B.W. Transdermal permeation modulation by cyclodextrins: a mechanistic study. Pharm. Dev. Technol., 1998, 3(3), 283-96.
60. Bentley, M.V.; Vianna, R.F.; Wilson, S.; Collett, J.H. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol., 1997, 49(4), 397-402.
61. Vollmer, U.; Müller, B.W.; Peeters, J.; Mesens, J.; Wilffert. B.; Peters, T. A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats. J. Pharm. Pharmacol., 1994, 46(1), 19-22.
62. Klang, V.; Matsko, N.; Zimmermann, A.M.; Vojnikovic, E.; Valenta, C. Enhancement of stability and skin permeation by sucrose stearate and cyclodextrins in progesterone nanoemulsions. Int. J. Pharm., 2010, 393(1-2), 152-60.
63. Nagarsenker, M.S.; Amin, L.; Date, A.A. Potential of cyclodextrin complexation and liposomes in topical delivery of ketorolac: in vitro and in vivo evaluation. Aaps Pharmscitech, 2008, 9(4), 1165-70.
64. Kulkarni, M.; Nagarsenker, M. A Study on Improvement of Solubility of Rofecoxib and its effect on Permeation of Drug from Topical Formulations. Indian J. Pharm. Sci., 2008, 70(4), 466-71.
65. Maitre, M.M.; Longhi, M.R.; Granero, G.G. Ternary complexes of flurbiprofen with HP-beta-CD and ethanolamines characterization and transdermal delivery. Drug Dev. Ind. Pharm., 2007, 33(3), 311-26.
66. Sridevi, S.; Diwan, P.V. Optimized transdermal delivery of ketoprofen using pH and hydroxypropyl-beta-cyclodextrin as coenhancers. Eur. J. Pharm. Biopharm., 2002, 54(2), 151-4.
67. Martins, M.R.; Veiga, F. Promotores de permeação para a libertação transdérmica de fármacos: uma nova aplicação para as ciclodextrinas. Revista Brasileira de Ciências Farmacêuticas, 2002, 38, 33-54.
68. McCormack, B.; Gregoriadis, G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in Drug Deliv. J. Drug Targeting, 1994, 2(5), 449-54.
69. Chen, H.; Gao, J.; Wang, F.; Liang, W. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. Drug Deliv., 2007, 14(4), 201-8.
70. Jain, S.K.; Gupta, Y.; Jain, A.; Amin, S. Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery. Curr. Drug Deliv., 2008, 5(3), 207-14.
71. Maestrelli, F.; González-Rodríguez, M.L.; Rabasco, A.M.; Mura, P. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal Drug Deliv. Int. J. Pharm., 2005, 298(1), 55-67.
72. Jain, S.K.; Gupta, Y.; Jain, A.; Bhola, M. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery. Drug Deliv., 2007, 14(6), 327-35.
73. Loukas, Y.L.; Vraka, V.; Gregoriadis, G. Drugs, in cyclodextrins, in liposomes: a novel approach to the chemical stability of drugs sensitive to hydrolysis. Int. J. Pharm., 1998, 162(1-2), 137-142.
74. Piel, G.; Piette, M.; Barillaro, V.; Castagne, D.; Evrard, B.; Delattre, L. Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics. Int. J. Pharm., 2006, 312(1-2), 75-82.
75. Hatzi, P.; Mourtas, S.; Klepetsanis, P.G.; Antimisiaris, S.G. Integrity of liposomes in presence of cyclodextrins: effect of liposome type and lipid composition. Int. J. Pharm., 2007, 333(1-2), 167-76.
76. Puskas, I.; Csempesz, F. Influence of cyclodextrins on the physical stability of DPPC-liposomes. Colloids Surf B Biointerfaces, 2007, 58(2), 218-24.
77. Piel, G.; Piette, M.; Barillaro, V.; Castagne, D.; Evrard, B.; Delattre, L. Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes. Int. J. Pharm., 2007, 338(1-2), 35-42.
78. Fatouros, D.G.; Hatzidimitriou, K.; Antimisiaris, S.G. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur. J. Pharm. Sci., 2001, 13(3), 287-296.
79. Gillet, A.; Grammenos, A.; Compère, P.; Evrard, B.; Piel, G. Development of a new topical system: drug-in-cyclodextrin-indeformable liposome. Int. J. Pharm., 2009, 380(1-2), 174-80.
80. Hagiwara, Y.; Arima, H.; Miyamoto, Y.; Hirayama, F.; Uekama, K. Preparation and pharmaceutical evaluation of liposomes entrapping salicylic acid/gamma-cyclodextrin conjugate. Chem. Pharma. Bull. (Tokyo), 2006, 54(1), 26-32.
81. Pardeike, J.; Hommoss, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366(1-2), 170-184.
82. Müller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54(Supplement 1), S131-S155.
83. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled Drug Deliv. - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-77.
84. Cavalli, R.; Peira, E.; Caputo, O.; Gasco, M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int. J. Pharm., 1999, 182(1), 59-69.
85. Wongmekiat, A.; Yoshimatsu, S.; Tozuka, Y.; Moribe, K.; Yamamoto, K. Investigation of Drug Nanoparticle Formation by Co-grinding with Cyclodextrins: Studies for Indomethacin, Furosemide and Naproxen. J. Inclusion Phenom. Macrocyclic Chem., 2006, 56(1), 29-32.
86. Heuschkel, S.; Goebel, A.; Neubert, R.H. Microemulsions--modern colloidal carrier for dermal and transdermal Drug Deliv. J. Pharm. Sci., 2008, 97(2), 603-31.
87. Chen, H.; Chang, X.; Weng, T.; Zhao, X.; Gao, Z.; Yang, Y.; Xu, H.; Yang, X. A study of microemulsion systems for transdermal delivery of triptolide. J. Control. Release, 2004, 98(3), 427-436.
88. Hua, L.; Weisan, P.; Jiayu, L.; Hongfei, L. Preparation and evaluation of microemulsion of vinpocetine for transdermal delivery. Pharmazie, 2004, 59(4), 274-8.
89. Dalmora, M.E.; Oliveira, A.G. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int. J. Pharm., 1999, 184(2), 157-64.
90. Dalmora, M.E.; Dalmora, S.L.; Oliveira, A.G. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical antiinflammatory effect. Int. J. Pharm., 2001, 222(1), 45-55.
91. Ventura, C.A.; Tommasini, S.; Falcone, A.; Giannone, I.; Paolino, D.; Sdrafkakis, V.; Mondello, M.R.; Puglisi, G. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. Int. J. Pharm., 2006, 314(1), 37-45.
92. Loftsson, T.; Fridriksdóttir, H.; Thórisdóttir, S.; Stefánsson, E.; The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-ß-cyclodextrin formulations. Int. J. Pharm., 1994, 104(2), 181-184.
93. Mora, M.J.; Longhi, M.R.; Granero, G.E. Synthesis and characterization of binary and ternary complexes of diclofenac with a Methyl-[beta]-CD and monoethanolamine and in vitro transdermal evaluation. Eur. J. Med. Chem., 2010, 45(9), 4079-88.
94. Reddy, D.N.; Udupa, N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev. Ind. Pharm., 1993, 19(7), 843-852.
95. Maitre, M.M.; Longhi, M.R.; Granero, G.G. Ternary complexes of flurbiprofen with HP-beta-CD and ethanolamines characterization and transdermal delivery. Drug Dev. Ind. Pharm., 2007, 33(3), 311-326.
96. Siguroardottir, A.M.; Loftsson, T. The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin. Int. J. Pharm., 1995, 126(1-2), 73-78.
97. Loftson, T.; Frioriksdottir, G.; Jonsdottir, B. The influence of 2- hydroxypropyl ß cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone. Drug Dev. Ind. Pharm., 1994, 20(9), 1699-1708.
98. Chang, S.L.; Banga, A.K. Transdermal iontophoretic delivery of hydrocortisone from cyclodextrin solutions. J. Pharm. Pharmacol., 1998, 50(6), 635-640.
99. Lin, S. Z.; Wouessidjewe, D.; Poelman, M. C.; Duchene, D. In-vivo evaluation of indomethacin/cyclodextrin complexes gastrointestinal tolerance and dermal antiinflammatory activity. Int. J. Pharm., 1994, 106(1), 63-67.
100. Sridevi, S.; Diwan, P.V.R. Optimized transdermal delivery of ketoprofen using pH and hydroxypropyl-beta-cyclodextrin as coenhancers. Eur. J. Pharm. Biopharm., 2002, 54(2), 151-154.
101. Doliwa, A.; Santoyo, S.; Ygartua, P. Transdermal iontophoresis and skin retention of piroxicam from gels containing piroxicam: Hydroxypropyl-beta-cyclodextrin complexes. Drug Dev. Ind. Pharm., 2001, 27(8), 751-758.
102. Jug, M.; Bećirević-Laćan, M.; Kwokal, A.; Cetina-Cizmek, B. Influence of cyclodextrin complexation on piroxicam gel formulations. Acta Pharm., 2005, 55(3), 223-236